NYSE - Delayed Quote USD

Charles River Laboratories International, Inc. (CRL)

Compare
187.96 -3.23 (-1.69%)
At close: September 6 at 4:00 PM EDT
187.96 0.00 (0.00%)
After hours: September 6 at 5:29 PM EDT
Loading Chart for CRL
DELL
  • Previous Close 191.19
  • Open 191.10
  • Bid 178.27 x 900
  • Ask 258.00 x 800
  • Day's Range 186.56 - 191.62
  • 52 Week Range 161.65 - 275.00
  • Volume 517,681
  • Avg. Volume 644,519
  • Market Cap (intraday) 9.705B
  • Beta (5Y Monthly) 1.37
  • PE Ratio (TTM) 22.48
  • EPS (TTM) 8.36
  • Earnings Date Nov 6, 2024 - Nov 11, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 224.59

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

www.criver.com

20,400

Full Time Employees

December 30

Fiscal Year Ends

Recent News: CRL

View More

Research Reports: CRL

View More

Performance Overview: CRL

Trailing total returns as of 9/6/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

CRL
20.49%
S&P 500
13.39%

1-Year Return

CRL
7.99%
S&P 500
20.27%

3-Year Return

CRL
58.19%
S&P 500
19.25%

5-Year Return

CRL
40.82%
S&P 500
81.73%

Compare To: CRL

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CRL

View More

Valuation Measures

Annual
As of 9/6/2024
  • Market Cap

    9.70B

  • Enterprise Value

    12.36B

  • Trailing P/E

    22.48

  • Forward P/E

    17.67

  • PEG Ratio (5yr expected)

    1.95

  • Price/Sales (ttm)

    2.38

  • Price/Book (mrq)

    2.61

  • Enterprise Value/Revenue

    3.03

  • Enterprise Value/EBITDA

    12.29

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    10.83%

  • Return on Assets (ttm)

    4.99%

  • Return on Equity (ttm)

    12.60%

  • Revenue (ttm)

    4.08B

  • Net Income Avi to Common (ttm)

    431.79M

  • Diluted EPS (ttm)

    8.36

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    179.21M

  • Total Debt/Equity (mrq)

    75.30%

  • Levered Free Cash Flow (ttm)

    376.42M

Research Analysis: CRL

View More

Company Insights: CRL

People Also Watch